Synthego

Synthego is a pioneering biotechnology company that has established itself as a key enabler in the CRISPR and molecular diagnostics sectors. By focusing on the engineering and scalable manufacturing of high-performance reagents like synthetic gRNA, nucleases (e.g., SpCas9, hfCas12Max), and diagnostic enzymes, it serves both academic/industrial research and clinical development pipelines. The company supports cell and gene therapy advancement through its GMP manufacturing capabilities and IND submission support, while also addressing the growing demand for rapid, reliable molecular diagnostics with its lyophilized, point-of-care-ready reagents. Synthego operates as a critical infrastructure provider, bridging the gap between discovery and clinical application.

Engineering and scalable manufacturing platform for synthetic biology components, including synthetic guide RNA (gRNA), engineered CRISPR nucleases (e.g., SpCas9, hfCas12Max), base editors (e.g., AccuBase CBE), and molecular diagnostics reagents (e.g., lyophilized isothermal amplification kits, PCR enzymes).

Synthego competes in the CRISPR research tools market against companies like Integrated DNA Technologies (IDT), Thermo Fisher Scientific, and Horizon Discovery. In GMP manufacturing for therapies, it faces competition from CDMOs like Lonza and Catalent. In molecular diagnostics reagents, it challenges giants such as New England Biolabs, Qiagen, and Thermo Fisher.